The indian pharma

 Blincyto (blinatumomab) is a prescription medication used to treat certain types of acute lymphoblastic leukemia (ALL). It is given as an intravenous infusion (injection into a vein) by a healthcare professional. The recommended dosage of Blincyto depends on the patient's body weight and medical history. The starting dose is typically 9 mcg per day, which is gradually increased over the first few days of treatment to a maintenance dose of 28 mcg per day. The dosage may be adjusted based on the patient's response to the medication and any side effects. Blincyto works by attaching to two proteins called CD19 and CD3, which are found on the surface of certain types of leukemia cells and immune cells. By attaching to CD19 and CD3, Blincyto helps to activate the immune system and destroy the cancer cells. Common side effects of Blincyto include fever, chills, headache, nausea, fatigue, and infections. Blincyto can also cause serious side effects, such as cytokine release syndr...

  Monjuvi (tafasitamab) is a prescription medication used to treat certain types of B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL). It is given as an intravenous infusion (injection into a vein) by a healthcare professional. The recommended dosage of Monjuvi is 12 mg/kg of body weight administered on days 1, 4, 8, 15, and 22 of a 28-day treatment cycle for a total of 6 cycles. The dosage may be adjusted based on the patient's response to the medication and any side effects. Monjuvi works by attaching to a protein called CD19, which is found on the surface of certain types of B-cells, including those that make up DLBCL. By attaching to CD19, Monjuvi can help to destroy the cancer cells and slow down the growth of the tumor. Common side effects of Monjuvi include fatigue, diarrhea, fever, low white blood cell count, and infections. Monjuvi can also cause serious side effects, such as infusion-related reactions, low blood pressure, and severe infections. Patient...

 Trodelvy (sacituzumab govitecan) is a prescription medication used to treat metastatic triple-negative breast cancer (TNBC) and metastatic urothelial cancer. It is given as an intravenous infusion (injection into a vein) by a healthcare professional. The recommended dosage of Trodelvy is 10 mg/kg of body weight administered on days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity. The dosage may be adjusted based on the patient's response to the medication and any side effects. Trodelvy works by targeting a protein called Trop-2, which is overexpressed in certain types of cancer cells, including TNBC and urothelial cancer. By attaching to Trop-2, Trodelvy delivers a chemotherapy drug directly to the cancer cells, which can help to destroy the cancer cells and slow down the growth of the tumor. Common side effects of Trodelvy include nausea, diarrhea, fatigue, hair loss, decreased appetite, and low white blood cell count. Trodelvy can also...

 Retevmo (selpercatinib) is a prescription medication used to treat certain types of thyroid cancer and non-small cell lung cancer (NSCLC) that have specific genetic mutations. It is taken orally in the form of capsules. The recommended dosage of Retevmo depends on the patient's body weight and medical history. For the treatment of thyroid cancer, the recommended dose is 120 mg taken orally twice daily (total of 240 mg per day) with food. For the treatment of NSCLC, the recommended dose is 160 mg taken orally twice daily (total of 320 mg per day) with food. Retevmo works by blocking the activity of specific proteins that promote the growth and spread of cancer cells. By blocking the activity of these proteins, Retevmo can slow down or stop the growth of the cancer cells. Common side effects of Retevmo include diarrhea, nausea, vomiting, constipation, fatigue, and decreased appetite. Retevmo can also cause serious side effects, such as high blood pressure, liver problems, and ...

  Tukysa (tucatinib) is a prescription medication used to treat HER2-positive breast cancer. It is taken orally in the form of tablets. The recommended dosage of Tukysa is 300 mg taken orally twice daily (total of 600 mg per day) in combination with trastuzumab and capecitabine, two other medications used to treat breast cancer. Treatment with Tukysa may continue as long as the patient continues to benefit from it and does not experience unacceptable side effects. Tukysa works by inhibiting the growth of HER2-positive breast cancer cells. HER2 is a protein that promotes the growth and division of cancer cells. By blocking the activity of HER2, Tukysa can slow down or stop the growth of the cancer cells. Common side effects of Tukysa include diarrhea, nausea, vomiting, fatigue, and liver problems. Tukysa can also cause serious side effects, such as severe diarrhea, liver problems, and lung problems. Patients should inform their healthcare provider immediately if they experienc...

  Enhertu (trastuzumab deruxtecan) is a prescription medication used to treat HER2-positive breast cancer. It is given as an intravenous injection (IV) by a healthcare professional. The dosage of Enhertu depends on the patient's body weight and medical history. It is typically given at a dose of 5.4 mg/kg every three weeks, with a maximum dose of 900 mg per infusion. The duration of treatment varies depending on the response to the medication and the severity of the disease. Enhertu works by attaching to HER2-positive cancer cells, which are cells that have too much of a protein called human epidermal growth factor receptor 2 (HER2) on their surface. This attachment helps to destroy the cancer cells and slow down the growth of the tumor . Common side effects of Enhertu include nausea, fatigue, vomiting, decreased appetite, hair loss, and constipation. Enhertu can also cause serious side effects, such as lung problems, heart problems, and infusion-related reactions. Patients sh...